Chloditan, mitotan, o,p'-DDD — modern vi ews and evaluations
Vol. 22 No. 3 (2017), REVIEWS
Vol. 22 No. 3 (2017)

Chloditan, mitotan, o,p'-DDD — modern vi ews and evaluations

REVIEWS
Published September 28, 2017
A.S. Mikosha
SI «V.P. Komisarenko Institute of Endocrinology and Metabolism, Natl. Acad. Med. Sci. of Ukraine»
E.I. Kovzun
SI «V.P. Komisarenko Institute of Endocrinology and Metabolism, Natl. Acad. Med. Sci. of Ukraine»
N.D. Tron’ko
SI «V.P. Komisarenko Institute of Endocrinology and Metabolism, Natl. Acad. Med. Sci. of Ukraine»
Pdf (Українська)

Keywords

chloditan, mitochondria, Itsenko-Cushing’s disease, adrenocortical cancer.

How to Cite

Mikosha, A., Kovzun, E., & Tron’ko, N. (2017). Chloditan, mitotan, o,p’-DDD — modern vi ews and evaluations. Endokrynologia, 22(3), 284-292. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/91
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Clinical and experimental data of studies on o,p’-DDD (mitotane, lisodren) are summarized in the review. Clinical experience indicates the effectiveness of the o,p’-DDD use in patients with inoperable cancer of the adrenal cortex. It is also used to treat the Itsenko – Cushing’s disease and hypercorticism caused by ectopic ACTH secretion.
o,p’-DDD causes a number of structural and biochemical changes that cause the suppression of the steroid hormone synthesis and the development of apoptosis in cells of the adrenal cortex. The decrease in the activity of NADP-reducing enzymes, the decrease in glutathione content, and the change in the composition and properties of mitochondrial
membranes are of particular importance among the biochemical disorders caused by o,p’-DDD in the adrenal cortex. Probably an impairment of the biochemical properties of mitochondria lies at the basis of the adrenocorticolytic action of o,p’-DDD. 

Pdf (Українська)

References

1. Bergenstal DM, Lipsett MB, Moy RH, Hertz R. Regression of adrenal cancer and suppression of adrenal function in man by o,p’DDD. Transactions Association American Physicians. 1959;72: 341-50.
2. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94(6):1853-78.
3. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a populationbased study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579-86.
4. Southren AL, Weisenfeld S, Laufer A, Goldner MG. Effect of o,p’-DDD in a patient with Cushing’s syndrome. J Clin Endocrinol Metab. 1961;21(2):201-8.
5. Bledsoe T, Island DP, Ney RL, Liddle GW. An effect of o,p’-DDD on the extra-adrenal metabolism of cortisol in man. J Clin Endocrinol Metab. 1964;24(12):1303-11.
6. Комиссаренко ВП, Резников АГ. Ингибиторы функции коры надпочечных желез. Київ: Здоров’я, 1972:374 с. (Komissarenko VP, Reznikov AG. Inhibitors of adrenal cortex function. Kyiv: Zdorovya, 1972:374 p.).
7. Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncology. 2012;23 (Suppl. 7):vii131-vii138.
8. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer. 2005;12(3):667-80.
9. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27(27):4619-29.
10. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551-64.

Downloads

Download data is not yet available.